Claims for Patent: 8,658,774

Summary for Patent: 8,658,774

Title:	Meditopes and related meditope-monoclonal antibody delivery systems, synthesis and therapeutic uses thereof
Abstract:	Meditope variants and methods for their use are provided herein. A meditope variant as described herein comprises a peptide having a sequence CQFDLSTRRLKC (SEQ ID NO:1) or CQYNLSSRALKC (SEQ ID NO:2) that has one or more modifications at of least one amino acid residue of the sequence. Multivalent meditope variant tethering entities are also provided. Such entities may include two or more meditopes coupled via a long linker, multivalent scaffold, biotin-streptavidin, or IgG Fc domain. Further, methods of treating, imaging or diagnosing a disease or condition are provided. Such methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, the pharmaceutical compound comprising an antibody-meditope complex; a multivalent tethering agent in combination with a monoclonal antibody or functional fragment thereof; or a combination thereof.
Inventor(s):	Williams; John C. (Monrovia, CA), Horne; David A. (Duarte, CA), Ma; Yuelong (Duarte, CA), Chang; Heng Wei (Foster City, CA)
Assignee:	City of Hope (Duarte, CA)
Application Number:	13/270,207
Patent Claims:	1. A method of purifying a monoclonal antibody or antigen-binding fragment thereof, comprising contacting a solution containing the monoclonal antibody or antigen-binding fragment thereof with a peptide coupled to a solid support, such that a meditope binding interface of the monoclonal antibody or fragment thereof binds to the peptide, and isolating the antibody or fragment, thereby purifying the antibody or fragment, wherein the monoclonal antibody is cetuximab, and wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 5, 6, 7, 8, 21, 22, 26, 32, and 33. 2. The method of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 7 or 8. 3. The method of claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 6, and 22. 4. The method of claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 7, 8, 22, and 26. 5. The method of claim 1, wherein the peptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7, 8, 21, 22, 26, 32, and 33. 6. The method of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO:32. 7. A method of purifying a monoclonal antibody or antigen-binding fragment thereof, comprising: contacting a solution containing the monoclonal antibody or antigen-binding fragment thereof with a peptide coupled to a solid support, such that a meditope binding interface of the monoclonal antibody or fragment thereof binds the peptide, and isolating the antibody or fragment, thereby purifying the antibody or fragment, wherein the monoclonal antibody is cetuximab, and wherein the peptide comprises the sequence of SEQ ID NO: 32. 8. A method of purifying a monoclonal antibody or antigen-binding fragment thereof, comprising contacting a solution containing the monoclonal antibody or antigen-binding fragment thereof with a peptide coupled to a solid support, such that a meditope binding interface of the monoclonal antibody or fragment thereof binds to the peptide, and isolating the antibody or fragment, thereby purifying the antibody or fragment, wherein the monoclonal antibody is cetuximab, and wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7, 8, 21, 22, 26, 32, and 33.

Details for Patent 8,658,774

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2030-10-08
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2030-10-08